Last updated on April 2020

Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)


Brief description of study

To evaluate the safety and tolerability of escalating doses GX-I7 in combination with standard dose pembrolizumab, and to evaluate objective response rate (ORR) in subjects with refractory or relapsed TNBC

Clinical Study Identifier: NCT03752723

Find a site near you

Start Over

National Cancer Center

Goyang-si, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Severance Hospital

Seoul, Korea, Republic of
  Connect »

Ajou Medical Center

Suwon-si, Korea, Republic of
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Gangnam Severance Hospital

Seoul, Korea, Republic of
  Connect »

Seoul ST.Mary's Hospital

Seoul, Korea, Republic of
  Connect »